SEC Form 10-K filed by Palatin Technologies Inc.
$PTN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2021 | $2.00 → $5.00 | Buy | HC Wainwright & Co. |
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously
Obesity programs:Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideTopline results expected 1Q calendar year 2025General obesity, weight loss management, and rare neuroendocrine and genetic diseases, including hypothalamic obesityMultiple clinical trials targeted to commence 2H calendar year 2025 with long-acting MC4R peptide and/or MC4R oral small molecule compoundsDry eye disease and other ocular programs, ulcerative colitis, and diabetic nephropathy programs:Program specific licensing/collaboration and spinout discussions ongoing with multiple deals targeted for calendar year 2025CRANBURY, N.J., Jan. 28, 2025 /PRNewswire/ -- Palatin Tech
Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathyDemonstrated efficacy at 6 months71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr)71% of patients achieved improved or stabilized estimated glomerular filtration rate (eGFR)Bremelanotide therapy increased urinary VEGF levels in 37.5% of patients and reduced urinary synaptopodin losses in 36% of patientsCRANBURY, N.J., Dec. 19, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanoc
CRANBURY, N.J., Dec. 16, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant exercise inducement agreement (the "inducement agreement") with an institutional investor to exercise certain outstanding warrants that the Company issued in June 2024 and October 2023 totaling 3,907,679 shares of the Company's common stock for gross proceeds of approximately $3.4 million.
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
10-Q - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
SC 13G/A - PALATIN TECHNOLOGIES INC (0000911216) (Subject)
SC 13G - PALATIN TECHNOLOGIES INC (0000911216) (Subject)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment completed October 2024Topline results expected 1Q calendar year 2025Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compoundsGeneral obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesityDry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs:Investment bank engaged as a
CRANBURY, N.J., Nov. 8, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q1
Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1)Patient Dosing Commenced 3Q Calendar Year 2024Patient Enrollment Expected to be Completed Early 4Q Calendar Year 2024Topline Results Expected 1Q Calendar Year 2025Dry Eye Disease (DED): PL9643MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical StudiesFDA Confirms Protocols and EndpointsPatient Enrollment Start Expected 1Q Calendar Year 2025Topline Results Anticipated 4Q Calendar Year 2025Potential Partner Collaboration and Funding Discussions OngoingMale Sexual Dysfunction: Bremelanotide Co-Formulated with a PDE5i for the Treatment of Erectile Dysfunction (ED) in Patients That Do Not Resp